Alirocumab for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Alirocumab for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Alirocumab (Praluent) is a prescription antibody medication, administered by injection every two or four weeks, used to lower the cholesterol-carrying particles that clog arteries. In people with existing heart disease, it brought fewer heart attacks, strokes, and leg-artery complications, and possibly fewer deaths. Side effects are mostly minor injection-site reactions; effects of decades of extremely low cholesterol, or of use in pregnancy, are unknown. (Full Review)

Protocol

Standard label regimen
75 mg every 2 weeks or 300 mg every 4 weeks
Subcutaneous injection (under the skin); increased to 150 mg every 2 weeks if LDL response is inadequate after 4–8 weeks
Outcome-trial regimen
LDL target 25–50 mg/dL
Started at 75 mg every 2 weeks, increased to 150 mg as needed; switched to blinded placebo when LDL stayed below 15 mg/dL
Single versus split dosing
Single injection per dose
300 mg given as two 150 mg injections at different sites; any consistent time of day; a missed dose is taken within 7 days
Time to effect
Cardiovascular events
1–2 years
Differences in events emerged over the first one to two years
LDL lowering
Measured at 4–8 weeks
Circulating levels of the blocked liver protein fall within hours
Plaque changes
52–78 weeks
Coronary plaque regression on imaging

Benefits

Contraindications
  • History of a serious hypersensitivity reaction to alirocumab (e.g., hypersensitivity vasculitis, angioedema, or a reaction requiring hospitalization)
  • Pregnant women, especially in the second and third trimesters
  • Children younger than 8 years (not studied)
  • Severe kidney impairment (eGFR below 30 mL/min/1.73 m²) or severe liver impairment (Child-Pugh Class C), unless under specialist oversight
    •
Key Interactions
  • Other PCSK9-targeting drugs (evolocumab, inclisiran): Avoid outside trials
  • Statins (atorvastatin, rosuvastatin, simvastatin): Monitor
  • Other nonstatin LDL-lowering drugs (ezetimibe, bempedoic acid): Monitor
  • Fibrates (triglyceride-lowering drugs such as fenofibrate and gemfibrozil): Monitor
  • Anticoagulants and antiplatelets (blood thinners such as warfarin, apixaban, and clopidogrel): Caution
  • Other injectable drugs (insulin, semaglutide): Caution; no co-injection at the same site
  • Red yeast rice (monacolin K): Monitor
  • Berberine: Monitor
  • Additive LDL-lowering supplements (plant sterols, psyllium, niacin): Monitor
    •

Risk & Side Effects

  • High: Injection-site reactions; allergic and hypersensitivity reactions
    •
  • Medium: Anti-drug antibodies and loss of effect
    •
  • Low: Memory and thinking complaints; new-onset diabetes; muscle aches; upper respiratory and flu-like symptoms; liver enzyme elevations; eye events
    •
  • Speculative: Unknown effects of decades of very low LDL; fetal immune effects
    •

Monitoring

Marker Target Why
LDL cholesterol Below 70 mg/dL; below 55 mg/dL with established disease Main treatment response
Apolipoprotein B (apoB) Below 60 mg/dL; 40–50 mg/dL for aggressive longevity targets Counts all artery-clogging particles
Non-HDL cholesterol Below 90 mg/dL Captures remnant particles
Lipoprotein(a) Below 30 mg/dL (about 75 nmol/L) Inherited risk; modest drug effect
Triglycerides Below 100 mg/dL Remnant risk; affects calculated LDL
HbA1c Below 5.4% Tracks new-onset diabetes
Fasting glucose 75–90 mg/dL Early glucose change
ALT and AST ALT below 25 U/L Liver safety
High-sensitivity C-reactive protein Below 1.0 mg/L Residual inflammatory risk, unchanged by the drug
eGFR No established functional target; track change from own baseline Kidney status for dosing decisions
Creatine kinase No established functional target; track change from own baseline Muscle injury check if symptoms arise

Cadence: Baseline panel before the first injection (Lp(a) once); LDL and apoB 4–8 weeks after starting or changing the dose (just before the next injection on 300 mg monthly), then every 3–6 months in the first year and every 6–12 months once stable; HbA1c and liver enzymes every 6–12 months

Qualitative Assessment

  • Injection-site comfort (redness, swelling, or itching lasting beyond a few days)
  • Muscle comfort and exercise tolerance
  • Memory, focus, and word-finding
  • Energy and general well-being
  • Skin or facial swelling suggesting allergy
  • Dosing consistency (missed or delayed injections)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.